109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
放射性肺损伤的病理机制及新型纳米药物递送治疗策略
Authors Zhang X, Zhang Z, Huang M, Jin Y, Huang Y, Ji P , Ma Z
Received 4 July 2025
Accepted for publication 5 October 2025
Published 13 October 2025 Volume 2025:20 Pages 12431—12465
DOI https://doi.org/10.2147/IJN.S551477
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Dong Wang
Xiaohuo Zhang,1,* Zhiruo Zhang,2 Mi Huang,2 Yufan Jin,2 Youming Huang,2 Peng Ji,2,3,* Zhenchao Ma1,*
1Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, 313000, People’s Republic of China; 2School of Pharmacy, Taizhou University, Taizhou, Jiangsu, 225300, People’s Republic of China; 3Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Peng Ji, School of Pharmacy, Taizhou University, No. 93, Jichuan East Road, Taizhou, Jiangsu, 225300, People’s Republic of China, Email jipeng0213@163.com Zhenchao Ma, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, No. 1558 North Sanhuan Road, Huzhou, Zhejiang, 313000, People’s Republic of China, Email mazhenchao@hzhospital.com
Abstract: Radiation-induced lung injury (RILI), encompassing early radiation pneumonitis (RP) and late radiation-induced lung fibrosis (RILF), remains a major dose-limiting complication of thoracic radiotherapy. The pathological processes involve oxidative stress, DNA damage, inflammatory cascades (notably IL-1, IL-6, TNF-α, and TGF-β), and fibrotic remodeling, yet current therapies—such as corticosteroids and antifibrotic agents—provide only partial relief and are often accompanied by significant side effects. Recent advances in nano-drug delivery systems (NDDS) offer new opportunities to overcome these limitations through targeted pulmonary delivery, stimuli-responsive release, and synergistic modulation of pathological pathways. Nanoformulations, including hyaluronic acid-based carriers, ROS-responsive microspheres, and inhalable nanomedicines, demonstrate enhanced pulmonary bioavailability, reduced systemic toxicity, and multi-mechanistic therapeutic potential. With continued refinement of intelligent nanocarriers and integration of advanced diagnostic tools, NDDS holds strong promise for translating preclinical advances into precise, individualized therapies for RILI.
Keywords: radiation pneumonitis, radiation-induced lung injury, nano-drug delivery system, stimuli-responsive release, targeted drug delivery, lung-targeted nanomedicine
1Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, 313000, People’s Republic of China; 2School of Pharmacy, Taizhou University, Taizhou, Jiangsu, 225300, People’s Republic of China; 3Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Peng Ji, School of Pharmacy, Taizhou University, No. 93, Jichuan East Road, Taizhou, Jiangsu, 225300, People’s Republic of China, Email jipeng0213@163.com Zhenchao Ma, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, No. 1558 North Sanhuan Road, Huzhou, Zhejiang, 313000, People’s Republic of China, Email mazhenchao@hzhospital.com
Abstract: Radiation-induced lung injury (RILI), encompassing early radiation pneumonitis (RP) and late radiation-induced lung fibrosis (RILF), remains a major dose-limiting complication of thoracic radiotherapy. The pathological processes involve oxidative stress, DNA damage, inflammatory cascades (notably IL-1, IL-6, TNF-α, and TGF-β), and fibrotic remodeling, yet current therapies—such as corticosteroids and antifibrotic agents—provide only partial relief and are often accompanied by significant side effects. Recent advances in nano-drug delivery systems (NDDS) offer new opportunities to overcome these limitations through targeted pulmonary delivery, stimuli-responsive release, and synergistic modulation of pathological pathways. Nanoformulations, including hyaluronic acid-based carriers, ROS-responsive microspheres, and inhalable nanomedicines, demonstrate enhanced pulmonary bioavailability, reduced systemic toxicity, and multi-mechanistic therapeutic potential. With continued refinement of intelligent nanocarriers and integration of advanced diagnostic tools, NDDS holds strong promise for translating preclinical advances into precise, individualized therapies for RILI.
Keywords: radiation pneumonitis, radiation-induced lung injury, nano-drug delivery system, stimuli-responsive release, targeted drug delivery, lung-targeted nanomedicine